NCT02827617 2025-11-18
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Oncology Institute of Southern Switzerland
Completed
Clinical Trials
5 trialsNCT03476655 2025-02-03
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
Johnson & Johnson Private Limited
Completed
NCT03425591 2022-10-06
FIRE
Janssen-Cilag Ltd.
Completed
NCT03720561 2022-01-03
EVIdeNCE
Janssen-Cilag S.p.A.
Completed
NCT02582320 2021-09-13
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed